Increasing adoption of multiplexing technologies across clinical diagnostics, pharmaceutical and biotech research, academic research, and CRO environments is accelerating the evolution of ...
AUSTIN, Texas, Feb. 24, 2020 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that the company has submitted an application to the U.S. Food and Drug Administration (FDA) for 510(k) ...
Luminex Corporation LMNX recently submitted an application to the FDA, seeking a 510(k) clearance of the VERIGENE II Respiratory Flex Assay. It is the second VERIGENE II assay to be submitted to the ...
Viral panel is designed to test for eight pathogens in up to 96 patients. FDA granted 510(k) approval to Luminex’ xTAG Respiratory Viral Panel FAST (RVP FAST) test for respiratory infections. Designed ...
Dr. Stephen will cover the process of developing and manufacturing reliable Luminex biomarker assays, as well as using those assays to test samples. She will examine the development of Ampersand ...
Invitrogen ProcartaPlex and QuantiGene Plex assays offer the unique ability of a multi-omics high-throughput approach by utilizing the Luminex platform. Genomic and proteomic workflows can be combined ...
In preclinical proteomics, speed and accuracy are paramount. Increasingly, scientists must capture more data in less time while consuming minimal sample. Given the throughputs required for efficient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results